ALZN · Alzamend Neuro, Inc.
$1.31
-0.04 (-2.96%)
At close · Jul 31
Going-concern doubt
— flagged Jul 22, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors create substantial doubt about our ability to continue as a going concern for at least one year after the date that our audited financial statements are issued.”View the 10-K filed Jul 22, 2026
Market Cap
$6.28M
Shares
4.79M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Capacity | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2026-03-06 | $3,000,000 | — | — | — | 10-Q , filed 2026-03-11 |